Omar Eladl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Omar Eladl has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Keiko Kondo
Institute of Advanced Energy, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan
2 shared publications - Masato Katahira
Institute of Advanced Energy, Kyoto University
2 shared publications Shady Estfanous
Faculty of Pharmacy, Egypt-Japan University of Science and Technology (E-JUST), Alexandria, Egypt; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Capital University (formerly Helwan), Ain Helwan, Helwan, Cairo 11795, Egypt
2 shared publications- Takashi Nagata
Institute of Advanced Energy, Kyoto University
2 shared publications - Yudai Yamaoki
Institute of Advanced Energy, Kyoto University, Gokasho, Uji, Kyoto 611-0011, Japan
2 shared publications Alaa Abdelhady
Faculty of Pharmacy, King Salman International University (KSIU), Ras Sudr, South Sinai, Egypt
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 99
Selective sustainable spectrophotometric techniques for simultaneous estimation of certain binary and ternary mixtures of anti-infective drugs: application in pharmaceutical formulations and spiked human plasma
A set of green, selective, sustainable, and rapid UV spectrophotometric techniques combined with chemometric models was established for the simultaneous estimation of metronidazole (MET), diloxanide furoate (DIL), and mebeverine hydrochloride (MEB) in overlapping binary and ternary mixtures without prior chemical separation. A total of 25 synthetic mixtures were prepared for model development and partitioned into 17 mixtures for calibration and 8 for external validation. Principal component regression (PCR), classical least squares (CLS), and partial least squares (PLS) models were constructed. The PLS framework utilized the SIMPLS algorithm, retaining 3–5 latent variables determined by the minimum root mean square error of cross-validation (RMSECV). PCR retained 4–6 principal components, optimized by cumulative variance and predicted residual error sum of squares (PRESS) minimization. Model validation was performed using RMSE, RMSECV, root mean square error of prediction (RMSEP), and the coefficient of determination ( $${R}^{2}$$ ), and bias metrics. The optimized PLS model achieved RMSEP values ranging from 0.12 to 0.61 µg mL⁻ 1 . Analytical performance was evaluated using external prediction errors, recovery, precision, and statistical comparison with the reported method. The established chemometric models were successfully applied to synthetic mixtures, pharmaceutical formulations, and drug-spiked human plasma as a proof-of-concept assessment of performance in a complex biological matrix. The overall eco-friendliness of the procedure was additionally verified using comprehensive green metrics, supporting its potential as a sustainable alternative for pharmaceutical quality control and further bioanalytical development.- 9 November 2026
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 12 (1) , 99
Open AccessSelective sustainable spectrophotometric techniques for simultaneous estimation of certain binary and ternary mixtures of anti-infective drugs: application in pharmaceutical formulations and spiked human plasma
A set of green, selective, sustainable, and rapid UV spectrophotometric techniques combined with chemometric models was established for the simultaneous estimation of metronidazole (MET), diloxanide furoate (DIL), and mebeverine hydrochloride (MEB) in overlapping binary and ternary mixtures without prior chemical separation. A total of 25 synthetic mixtures were prepared for model development and partitioned into 17 mixtures for calibration and 8 for external validation. Principal component regression (PCR), classical least squares (CLS), and partial least squares (PLS) models were constructed. The PLS framework utilized the SIMPLS algorithm, retaining 3–5 latent variables determined by the minimum root mean square error of cross-validation (RMSECV). PCR retained 4–6 principal components, optimized by cumulative variance and predicted residual error sum of squares (PRESS) minimization. Model validation was performed using RMSE, RMSECV, root mean square error of prediction (RMSEP), and the coefficient of determination ( $${R}^{2}$$ ), and bias metrics. The optimized PLS model achieved RMSEP values ranging from 0.12 to 0.61 µg mL⁻ 1 . Analytical performance was evaluated using external prediction errors, recovery, precision, and statistical comparison with the reported method. The established chemometric models were successfully applied to synthetic mixtures, pharmaceutical formulations, and drug-spiked human plasma as a proof-of-concept assessment of performance in a complex biological matrix. The overall eco-friendliness of the procedure was additionally verified using comprehensive green metrics, supporting its potential as a sustainable alternative for pharmaceutical quality control and further bioanalytical development. - 25 October 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254, 118573
The PHLPP paradox revisited: from canonical AKT phosphatases to signaling pseudoenzymes in human disease
- 25 October 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254, 118573
The PHLPP paradox revisited: from canonical AKT phosphatases to signaling pseudoenzymes in human disease
- 4 June 2026
- Published by Elsevier in Fitoterapia
- Vol. 192, 107327
Impact of arid-zone abiotic stress on phytochemical bioactivity: Enhancing chemotherapeutic synergy in breast cancer and personalized therapeutic algorithms
- 4 June 2026
- Published by Elsevier in Fitoterapia
- Vol. 192, 107327
Impact of arid-zone abiotic stress on phytochemical bioactivity: Enhancing chemotherapeutic synergy in breast cancer and personalized therapeutic algorithms
- 25 March 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 815, 153673
Epitranscriptomic RNA modifications in human disease: Cooperative networks, molecular mechanisms, and therapeutic opportunities
- 25 March 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 815, 153673
Epitranscriptomic RNA modifications in human disease: Cooperative networks, molecular mechanisms, and therapeutic opportunities
- 5 March 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 811, 153561
Beyond the obvious: Exploring the underappreciated dynamics and context-specific functions of lncRNAs
- 5 March 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 811, 153561
Beyond the obvious: Exploring the underappreciated dynamics and context-specific functions of lncRNAs
- 22 December 2025
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 39 (4) , 1-14
In-cell NMR spectroscopy: advancements, applications, challenges, and future directions in structural biology
In-cell nuclear magnetic resonance (NMR) spectroscopy has emerged as a leading technique in structural biology, providing atomic-level insights into the structures, dynamics, and interactions of biomolecules within their native cellular environments. By bridging the gap between conventional in vitro studies and the complexity of living systems, in-cell NMR enables direct observation of biomolecular behavior under near-physiological conditions. This review highlights recent methodological advances that have expanded the scope and feasibility of in-cell NMR. Innovations in isotopic labeling, including selective incorporation strategies, have enhanced spectral resolution and sensitivity. Optimized delivery approaches, such as microinjection and electroporation, facilitate efficient introduction of labeled biomolecules into diverse cell types. The use of cryogenically cooled probes and high-field magnets further improves signal detection, enabling the study of low-abundance targets. We discuss key applications, including protein folding, conformational dynamics, biomolecular interaction networks, and nucleic acid structural rearrangements. In addition, in-cell NMR has proven invaluable for drug discovery, providing mechanistic insights into intracellular drug–target interactions. Despite these advances, challenges remain, including spectral overlap from endogenous components, low intracellular concentrations, and maintaining cell viability during extended experiments. Future developments integrating cryo-electron microscopy (cryo-EM), mass spectrometry (MS), hyperpolarization techniques, and advanced labeling strategies promise to enhance sensitivity, resolution, and applicability, solidifying in-cell NMR as an indispensable tool for probing biomolecular function in living cells.
- 22 December 2025
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 39 (4) , 1-14
In-cell NMR spectroscopy: advancements, applications, challenges, and future directions in structural biology
In-cell nuclear magnetic resonance (NMR) spectroscopy has emerged as a leading technique in structural biology, providing atomic-level insights into the structures, dynamics, and interactions of biomolecules within their native cellular environments. By bridging the gap between conventional in vitro studies and the complexity of living systems, in-cell NMR enables direct observation of biomolecular behavior under near-physiological conditions. This review highlights recent methodological advances that have expanded the scope and feasibility of in-cell NMR. Innovations in isotopic labeling, including selective incorporation strategies, have enhanced spectral resolution and sensitivity. Optimized delivery approaches, such as microinjection and electroporation, facilitate efficient introduction of labeled biomolecules into diverse cell types. The use of cryogenically cooled probes and high-field magnets further improves signal detection, enabling the study of low-abundance targets. We discuss key applications, including protein folding, conformational dynamics, biomolecular interaction networks, and nucleic acid structural rearrangements. In addition, in-cell NMR has proven invaluable for drug discovery, providing mechanistic insights into intracellular drug–target interactions. Despite these advances, challenges remain, including spectral overlap from endogenous components, low intracellular concentrations, and maintaining cell viability during extended experiments. Future developments integrating cryo-electron microscopy (cryo-EM), mass spectrometry (MS), hyperpolarization techniques, and advanced labeling strategies promise to enhance sensitivity, resolution, and applicability, solidifying in-cell NMR as an indispensable tool for probing biomolecular function in living cells.
- Open Access
- 16 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Biophysical and transcriptomic characterization of LL-37-derived antimicrobial peptide targeting multidrug-resistant Escherichia coli and ESKAPE pathogens
The emergence of multidrug-resistant (MDR) bacterial pathogens is an alarming global health threat that demands new therapeutic strategies beyond conventional antibiotics. Here, we present a rationally designed antimicrobial peptide (AMP) derived from mammalian cathelicidins and defensins that selectively targets bacterial membranes with low cytotoxicity toward mammalian cells. Circular dichroism spectroscopy revealed that the peptide adopts an α-helical conformation upon membrane interaction, a key feature of its mechanism. Surface plasmon resonance and isothermal titration calorimetry demonstrated high-affinity and selective binding to bacterial lipid membranes. Functionally, the peptide was strongly bactericidal against clinical MDR Escherichia coli (E. coli) and clinically important ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.). Compared with the parent peptide LL-37, our AMP exhibited lower minimum inhibitory concentrations (MICs) and faster bactericidal kinetics across both Gram-negative and Gram-positive strains. Calcein leakage assays, showing effective membrane disruption. Importantly, cytotoxicity experiments with human epithelial (Caco-2) and immune (THP-1) cells indicated low cytotoxicity at concentrations exceeding bactericidal levels, supporting a favorable therapeutic window. ELISA quantifications of cytokines (IL-6, TNF-α) further suggested immunomodulatory effects at bactericidal concentrations. Transcriptomic profiling of E. coli treated with sub-lethal concentrations of the peptide exhibited upregulation of bacterial stress response pathways and downregulation of vital metabolic processes, reflecting the complex antimicrobial action of the peptide. Collectively, these findings highlight this LL-37-derived AMP as a promising candidate for treating MDR bacterial infections caused by E. coli and ESKAPE pathogens and for guiding the development of next-generation antimicrobial agents.
- 16 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Open AccessBiophysical and transcriptomic characterization of LL-37-derived antimicrobial peptide targeting multidrug-resistant Escherichia coli and ESKAPE pathogens
The emergence of multidrug-resistant (MDR) bacterial pathogens is an alarming global health threat that demands new therapeutic strategies beyond conventional antibiotics. Here, we present a rationally designed antimicrobial peptide (AMP) derived from mammalian cathelicidins and defensins that selectively targets bacterial membranes with low cytotoxicity toward mammalian cells. Circular dichroism spectroscopy revealed that the peptide adopts an α-helical conformation upon membrane interaction, a key feature of its mechanism. Surface plasmon resonance and isothermal titration calorimetry demonstrated high-affinity and selective binding to bacterial lipid membranes. Functionally, the peptide was strongly bactericidal against clinical MDR Escherichia coli (E. coli) and clinically important ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.). Compared with the parent peptide LL-37, our AMP exhibited lower minimum inhibitory concentrations (MICs) and faster bactericidal kinetics across both Gram-negative and Gram-positive strains. Calcein leakage assays, showing effective membrane disruption. Importantly, cytotoxicity experiments with human epithelial (Caco-2) and immune (THP-1) cells indicated low cytotoxicity at concentrations exceeding bactericidal levels, supporting a favorable therapeutic window. ELISA quantifications of cytokines (IL-6, TNF-α) further suggested immunomodulatory effects at bactericidal concentrations. Transcriptomic profiling of E. coli treated with sub-lethal concentrations of the peptide exhibited upregulation of bacterial stress response pathways and downregulation of vital metabolic processes, reflecting the complex antimicrobial action of the peptide. Collectively, these findings highlight this LL-37-derived AMP as a promising candidate for treating MDR bacterial infections caused by E. coli and ESKAPE pathogens and for guiding the development of next-generation antimicrobial agents.
- 2 September 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 3) , 117297
Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential
- 2 September 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 3) , 117297
Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential
- Open Access
- 11 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29373
In-cell NMR reveals the first direct observation of endogenous interaction between HIV Tat protein and Tat RNA aptamer in human cells
RNA–protein interactions lie at the basis of numerous regulatory and functional cellular biological processes, including transcriptional control, RNA processing, nuclear export, and viral replication. Despite their fundamental biological significance, direct structural investigation of RNA–protein complexes in live human cells remains an unresolved problem due to resolution limits in spatial information, delivery of molecules, and real-time monitoring under native conditions. Existing studies rely on pre-existing in vitro complexes added to cells and therefore overlook important aspects of endogenous binding and localization. Here, we report the first in-cell nuclear magnetic resonance (NMR) study of the de novo formation of an RNA–protein complex in living human cells. By using a model system involving the HIV-1 Tat protein and its high-affinity RNA aptamer, we expressed Tat endogenously in HeLa cells and introduced the aptamer by electroporation. Direct observation was made of native complex formation within the intracellular milieu. In-cell NMR spectra exhibited characteristic chemical shift perturbations and nuclear Overhauser effect (NOE) signatures indicative of specific RNA–protein binding under physiological conditions. Comparison directly with in vitro spectra confirmed structural integrity and binding specificity in the intracellular environment. Remarkably, we obtained a partial NOE-based assignment of the RNA upon complexation with Tat in living cells—an unprecedented step towards cellular structural biology. Complementary confocal microscopy validated nuclear co-localization, enabling functionally relevant interaction. This work shows the first direct, real-time evidence for native RNA–protein complex assembly in human cells. It provides a new paradigm for probing RNA-mediated regulatory events in vivo and expands the horizon of therapeutic RNA design.
- 11 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 29373
Open AccessIn-cell NMR reveals the first direct observation of endogenous interaction between HIV Tat protein and Tat RNA aptamer in human cells
RNA–protein interactions lie at the basis of numerous regulatory and functional cellular biological processes, including transcriptional control, RNA processing, nuclear export, and viral replication. Despite their fundamental biological significance, direct structural investigation of RNA–protein complexes in live human cells remains an unresolved problem due to resolution limits in spatial information, delivery of molecules, and real-time monitoring under native conditions. Existing studies rely on pre-existing in vitro complexes added to cells and therefore overlook important aspects of endogenous binding and localization. Here, we report the first in-cell nuclear magnetic resonance (NMR) study of the de novo formation of an RNA–protein complex in living human cells. By using a model system involving the HIV-1 Tat protein and its high-affinity RNA aptamer, we expressed Tat endogenously in HeLa cells and introduced the aptamer by electroporation. Direct observation was made of native complex formation within the intracellular milieu. In-cell NMR spectra exhibited characteristic chemical shift perturbations and nuclear Overhauser effect (NOE) signatures indicative of specific RNA–protein binding under physiological conditions. Comparison directly with in vitro spectra confirmed structural integrity and binding specificity in the intracellular environment. Remarkably, we obtained a partial NOE-based assignment of the RNA upon complexation with Tat in living cells—an unprecedented step towards cellular structural biology. Complementary confocal microscopy validated nuclear co-localization, enabling functionally relevant interaction. This work shows the first direct, real-time evidence for native RNA–protein complex assembly in human cells. It provides a new paradigm for probing RNA-mediated regulatory events in vivo and expands the horizon of therapeutic RNA design.